HIV treatment and care among Italian inmates: a one-month point survey

R. Monarca¹, G. Madeddu², R. Ranieri³, S. Carbonara⁴, G. Leo⁵, M. Sardo⁶, F. Choroma⁷, S. Casari⁸, D. Marri⁹, A. A. Muredda², F. A. Nava¹⁰, S. Babudieri²* and SIMSPe–SIMIT Group

Abstract

Background: HIV infection, with an estimated prevalence be between 2 and 50 times those of the general adult population is a major health challenge for prison authorities worldwide. Since no nationwide surveillance system is present in Italy, data on HIV prevalence and treatment in prisons are limited to only a few and small observational studies. We aimed to estimate HIV prevalence and obtain an overview on diagnostic and therapeutic activities concerning HIV infection in the Italian penitentiary system.

Methods: We piloted a multi-centre cross-sectional study investigating the prevalence of HIV infection and assessing HIV-related medical activities in Italian correctional institutions.

Results: A total of 15,675 prisoners from 25 institutions, accounting for approximately one-fourth of the prison inmates in Italy, were included in the study, of whom, 97.7 % were males, 37.1 % foreigners and 27 % had a history of intravenous drug addiction. HIV-tests were available in 42.3 % of the total population, with a known HIV Infection proportion of 5.1 %. In the month prior to the study, 604 of the 1,764 subjects who entered prison were tested for HIV, with a HIV-positive prevalence of 3.3 %. Among the 338 HIV-positive prisoners, 81.4 % were under antiretroviral treatment and 73.5 % showed undetectable HIV-RNA. In 23/338 (6.8 %) a coinfection with HBV and in 189/338 (55.9 %) with HCV was also present. Among the 67 (19.8 %) inmates with HIV who did not receive HIV treatment, 13 (19.5 %) had T-CD4+ count <350 cells/mm³ and 9 (69.2 %) of these had refused the treatment. The majority of the inmates with HIV-infection were on a PI-based (62.5 %) or on NNRTIs-based (24.4 %) regimen. Only a minority of patients received once daily regimens (17.2 %).

Conclusions: Although clinical and therapeutic management of HIV infection remains difficult in Italian prisons, diagnostics, treatment and care were offered to the majority of HIV-infected inmates. Specific programs should be directed towards the prison population and strict cooperation between prison and health institutions is needed to increase HIV treatment.

Keywords: HIV, Patient care, Screening, Antiretroviral treatment, Medication adherence

Background

HIV is a major health challenge for prison authorities worldwide. HIV prevalence within prisons is estimated to be between 2 and 50 times those of general adult populations. Available studies show an HIV prevalence ranging from 0.6 % in the UK to 6 % in Spain and 7.2 % in Italy [1–7].
unmet due to the limitations of the Italian penitentiary system, such as severe budget constraints leading to under-resourced prison settings, prison overcrowding, poor condition of the existing health facilities, under-trained and underpaid prison staffing, frequent inmate transfer between prisons or prison wings, court attendance and hospital visits, lack of a national correctional healthcare database and especially the low offering and execution of HIV screening [9–11].

Moreover, the data on treatment of HIV infection in prisons are limited to only a few observational studies, thus undermining current policy for improving prison health care system [10–14].

The aims of this study were firstly, to evaluate the prevalence of HIV infection among new entry inmates, secondly, to evaluate the number of HIV infected inmates who were actually treated and thirdly to describe the antiretroviral treatments offered and report the reasons for lack of treatment.

Methods
A multi-centre cross-sectional survey was carried out from 1 to 30 July 2013 to investigate the prevalence of HIV infection and to assess HIV-related diagnostic and therapeutic activities in Italian correctional institutions. The prevalence of HIV infection was estimated in the imprisoned population on July 31, 2013. Data on HIV testing was evaluated both in the entire prison population and in the prison entrants during the study period. A questionnaire was emailed to the 206 Italian prisons that were voluntarily answered by health professionals based in the prison establishments using information in medical records. The following data was recorded only for inmates who were present during the study period: general data (sex, ethnicity and drug use), HIV data (HIV testing, viro-immunological profile, visit schedule), HIV treatment data (setting, method, frequency of drug dispensation, type of antiretrovirals used, medication refusal). Returned surveys were collected and consolidated using build-in functions of Microsoft Excel. Where gaps in the questionnaire data remained, prison administrative bodies and experts were contacted via e-mail or telephone and requests for specific information were made.

All studies regarding the Italian Penitentiary System have been nationally approved by the Ethics Committee of the University of Rome Tor Vergata (Registro Sperimentazioni 73/05). No specific consent was required since data were collected in anonymous and aggregate form.

Statistical analysis
Data was analyzed using the SPSS statistical software, version 6.0. Results are expressed as proportions. When applicable, a two-tailed hypothesis testing for difference in proportions was used (Proportion Test); a $p$ value of $<0.05$ was considered significant.

Results
Prison population in Italy
On 31 July 2013 Italian prisons counted 64,873 detainees, almost one per 1,000 inhabitants. Foreign detainees were 22,744. It is worth noting that foreign prisoners had more than doubled between 1990 (15 %) and 2013 (35 %). At the time of the study, Italy's prisons were the most crowded in the European Union with occupancy at more than 142 % of capacity.

Survey population
On July 31, a total of 15,675 prisoners (15,318 males and 357 females) were included in the survey, accounting for 24.2 % of the total Italian inmates. Thirty-five of the 206 correctional institutions in Italy from 16 of the 20 Italian regions voluntarily answered the questionnaire: 12 in Northern Italy ($n = 6,527$ inmates), 11 in Central Italy ($n = 3,846$ inmates) and 12 in Southern Italy ($n = 5,302$ inmates). The number of prisoners included in the survey ranged from 7.8 % to 69.1 % according to geographical area. Overall, the institutes in Northern Italy accounted for nearly one-third (32.7 %) of the prisoners included in the survey, compared with 21.5 % in Central Italy and 22.7 % in Southern Italy. During the month prior to the survey 1,764 adults were imprisoned. Table 1 shows the characteristics of inmates entered into the study, according to Italian region. The majority of prisoners were men (97.7 %) with native born Italians accounting for 62.9 % of inmates and foreigners 37.1 % (range 2.0 % - 88.0 %). The vast majority of foreign prisoners included individuals from Morocco (19.0 %), Romania (15.8 %), Albania (12.5 %), Tunisia (12.1 %), Nigeria (4.2 %), Algeria (2.6 %), Egypt (2.0 %) and Senegal (1.8 %). Just under one-third of prison inmates (27.0 %) had a history of heroin or cocaine misuse.

HIV and other infectious diseases testing
Among the participating penitentiary institutions, 35/35 (100 %) performed screening tests for HIV, HBV and HCV, 27/35 (77.1 %) for tuberculosis and 31/35 (88.6 %) for syphilis.

A voluntary HIV screening, as part of routine clinical evaluations, was available in 6,630 (42.3 %) of the total population at the time of the study and 338 (5.1 %), 330 (97.6 %) males and 8 (2.4 %) females, of these inmates were HIV-infected. Among the 338 HIV-infected inmates 266/338 (78.7 %) were Italian, 72/338 (21.3 %) were foreigners, 23/338 (6.8 %) were also HBsAg-positive and 189/388 (55.9 %) had anti-HCV antibodies.

Regarding risk factors for HIV infection, 175/338 (51.7 %) reported being intravenous drug users (IVDU),
16/338 (4.7 %) were men having sex with men (MSM) and 147/338 (43.5 %) declared sexual contact risk. Furthermore, 85/163 (52.1 %) of non IVDU reported tattooing or body piercing with unsterile equipment.

When considering only the 72 HIV-infected foreigners, 49/72 (68.0 %) reported being IVDU, 20/72 (27.8 %) were heterosexuals and 3/72 (4.2 %) were MSM.

When considering only the 1,764 subjects incarcerated during the month prior to the survey, HIV-test was offered to 1,338 (75.8 %) at prison entry and 604 (45.1 %) of these accepted to be tested, 417 (31.2 %) refused, 276 (20.6 %) were waiting for the results and 41 (3.1 %) were not tested due to their release. Among the 604 tested inmates, 20 (3.3 %) were HIV-Ab positive.

Viro-immunological characteristics of treated patients
All the institutions provided information regarding access to viro-immunological parameters while in prison. Viral load measurement was performed in all of them, lymphocytes subsets immunophenotyping in 94.3 % and genotypic testing for HIV in 74.3 %.

An evaluation of the clinical data of 338 HIV-infected inmates, showed that 81.4 % were receiving an antiretroviral treatment (ART) and that 73.5 % showed an undetectable HIV-RNA (<50 copies/mL).

Fewer than 10 % of the detained patients on therapy, had CD4 lymphocyte counts below 200/mm³ (9.4 %), 18.2 % had between 200/mm³ and 349/mm³, 32.0 % between 350/mm³ and 500/mm³, and 36.4 % above 500/mm³. CD4 lymphocyte count was not available in 4 % of the inmates. By contrast, among the 67 inmates (19.8 %) who were not on ART, less than 5 % of the prisoners had CD4 lymphocyte counts below 200/mm³ (4.5 %), 15.0 % between 200/mm³ and 349/mm³, 10.4 % between 350/mm³ and 500/mm³, and 70.1 % had CD4 above 500/mm³. CD4 lymphocyte count was not available for 4 % of these patients.

HIV treatment and care
The majority of known HIV-positive inmates (275/338; 81.4 %) were receiving antiretroviral treatment at the time of the study. Of them, 172/275 (62.5 %) were receiving a protease inhibitor (PI)-based ART, 72 (21.0 %) a non-nucleoside reverse transcriptase inhibitors (NNRTIs)-based ART and 27 (9.8 %) raltegravir as an integrase inhibitor-based ART. The difference in the proportion of

| Region         | Number of institutes | Institutes participating in the survey | Total prisoners on July 31 | Prisoners participating in the survey | Male prisoners | History of drug misuse | Foreigners participating in the survey |
|----------------|----------------------|----------------------------------------|-----------------------------|---------------------------------------|----------------|------------------------|---------------------------------------|
| Abruzzo        | 7                    | 0                                      | 2047                        | 0                                     | 0              | 0                      | 0                                     |
| Basilicata     | 3                    | 0                                      | 483                         | 0                                     | 0              | 0                      | 0                                     |
| Calabria       | 12                   | 2                                      | 2651                        | 744 (36.3 %)                          | 696 (93.5 %)   | 105 (14.1 %)            | 161 (21.6 %)                          |
| Campania       | 17                   | 4                                      | 7999                        | 3230 (40.4 %)                         | 3230 (100 %)   | 867 (26.8 %)            | 422 (13.1 %)                          |
| Emilia Romagna | 13                   | 5                                      | 3759                        | 1570 (41.8 %)                         | 1507 (100 %)   | 545 (36.2 %)            | 861 (54.8 %)                          |
| Friuli Venezia Giulia | 5 | 1                                      | 845                         | 275 (32.5 %)                          | 275 (100 %)    | 59 (21.4 %)             | 172 (62.5 %)                          |
| Lazio          | 14                   | 1                                      | 7175                        | 739 (10.3 %)                          | 739 (100 %)    | 197 (26.6 %)            | 259 (35.0 %)                          |
| Liguria        | 7                    | 1                                      | 1764                        | 240 (13.6 %)                          | 240 (100 %)    | 100 (41.7 %)            | 105 (43.8 %)                          |
| Lombardia      | 19                   | 3                                      | 8961                        | 1869 (20.8 %)                         | 1868 (99.9 %)  | 633 (33.9 %)            | 644 (34.5 %)                          |
| Marche         | 7                    | 1                                      | 1108                        | 300 (27.1 %)                          | 279 (93.0 %)   | 63 (21.0 %)             | 138 (46.0 %)                          |
| Molise         | 3                    | 0                                      | 505                         | 0                                      | 0              | 0                      | 0                                     |
| Piemonte       | 13                   | 2                                      | 4870                        | 1760 (36.1 %)                         | 1,660 (94.3 %) | 346 (19.6)             | 694 (39.4 %)                          |
| Puglia         | 12                   | 1                                      | 4039                        | 428 (10.6 %)                          | 408 (95.3 %)   | 94 (21.9 %)             | 120 (28.0 %)                          |
| Sardegna       | 12                   | 1                                      | 2095                        | 165 (7.8 %)                           | 148 (89.6 %)   | 78 (47.2 %)             | 44 (26.6 %)                           |
| Sicilia        | 26                   | 3                                      | 6976                        | 735 (10.5 %)                          | 735 (100 %)    | 161 (21.9 %)            | 130 (17.7 %)                          |
| Toscana        | 18                   | 3                                      | 4135                        | 733 (17.7 %)                          | 733 (100 %)    | 232 (31.6 %)            | 271 (37.0 %)                          |
| Trentino Alto Adige | 3 | 1                                      | 405                         | 280 (69.1 %)                          | 260 (92.8 %)   | 50 (17.8 %)             | 224 (80.0 %)                          |
| Umbria         | 4                    | 2                                      | 1672                        | 504 (30.1 %)                          | 504 (100 %)    | 120 (23.8 %)            | 201 (39.9 %)                          |
| Valle d’Aosta  | 1                    | 0                                      | 278                         | 0                                      | 0              | 0                      | 0                                     |
| Veneto         | 10                   | 4                                      | 3106                        | 2103 (67.7 %)                         | 2036 (96.8 %)  | 582 (27.7 %)            | 1377 (65.5 %)                         |
| National Total | 206                  | 35                                      | 64,873                      | 15,675 (24.2 %)                       | 15,318 (97.7 %) | 4232 (27.0 %)           | 5761 (36.7 %)                         |
patients treated patients with PI-based regimens compared to those receiving NNRTIs-based regimens was statistically significant ($p < 0.005$).

PI-based antiretroviral regimens included atazanavir in 88 (32.0 %) patients, lopinavir (18.5 %) in 51, darunavir in 23 (8.4 %), fosamprenavir in 9 (3.3 %) and saquinavir in 1 (0.4 %), as shown in Table 2.

NNRTI-based ART regimens included efavirenz in 50 (18.2 %) patients, nevirapine in 9 (3.3 %), rilpivirine in 8 (2.9 %), etravirine in 5 (1.8 %). In 41/50 (82 %) patients efavirenz was included in the efavirenz-tenofovir-disoproxil-fumarate-emtricitabine co-formulation and in 6/8 (75 %) rilpivirine was part of the rilpivirine-tenofovir-disoproxil-fumarate-emtricitabine co-formulation (Table 2).

The backbone in the 275 HIV-positive inmates consisted of 194 (70.5 %) tenofovir-disoproxil-fumarate-emtricitabine, 41 (14.9 %) abacavir-lamivudine, 12 lamivudine-zidovudine (4.4 %), and 28 (10.2 %) other NRTI combinations (Table 2).

The medical visit schedule was on weekly basis in 4.3 % of prisoners under ART, on monthly basis in 32.9 %, on quarterly basis in 51.4 % and every 6 months in 11.4 %.

All the correctional institutes had medical facilities able to dispense antiretroviral drugs. Lack of HIV treatment in prisoners with CD4 lymphocyte count < 350/mm$^3$ was due to medication refusal (69.2 %), ongoing medical assessment (23.1 %) and other reasons including fear of side effects, cultural or ethnic beliefs, depression or delusional state (7.7 %).

Medication dispensing by nurse practitioners to those who were under ART occurred in prison (70 %) or at the medical unit (30 %). The methods for dispensing medications were: daily directly observed therapy (DOT, 42.8 %), keep-on-person (KOP, 31.4 %) with daily delivery and a mixed combination (25.7 %). Frequency of dispensing was once a day (17.2 %), twice a day (31.4 %) or ≥ 3 times a day (51.4 %). Once a day regimens were perceived to facilitate DOT by a majority (65.7 %) of the healthcare staff with only 25.7 % considering these regimens useless to DOT.

After prison release, nearly two-thirds (66.4 %) of the prisoners were followed up by infectious disease specialists.

### Discussion

This study was designed to provide a current picture of HIV prevalence, treatment and care in the Italian prison population.

The lack of a comprehensive surveillance system makes it difficult to estimate the prevalence of HIV-infected inmates in the Italian correctional system. Published prevalence data are usually taken from studies conducted on small numbers of prisons or in single regions, this hampering the achievement of definite data. Likewise, little is known about treatment of HIV among inmates [7, 10, 11, 14]. Medical assistance to HIV-infected individuals is a relevant issue in the community of inmates and treatment monitoring is essential to guarantee an appropriate use of antiretroviral drugs and high quality patient care [7, 10, 15–18]. Point-prevalence studies based on existing medical data in correctional institutes could help to better understand the spread of HIV as well as elaborate successful prevention and care strategies.

Although our findings are limited by the partial participation of the Italian penal institutes, they contribute to improve our knowledge on HIV infection, treatment and care among HIV-patients detained in Italy. In fact, with more than 15,000 inmates in 35 prisons distributed all over the country, our investigation includes nearly one-quarter of those incarcerated in Italy, with 27.0 % being IVDU and 37.1 % being foreigners at the time of the study.

Looking at the distribution of the participating prisons across the country and at the composition of HIV-risk factors among inmates, our data seems to be reasonably representative of the Italian prison population.

Despite the low rate of HIV testing identified in our study and the well-known difficulty in inmate patients to

| Table 2: Antiretroviral regimens received by the 275 HIV-infected inmates on ART |
|---------------------------------|--------|--------|
| **ANTIRETROVIRAL DRUGS**       | **n (%)** |
| **Protease inhibitors (PI)**   |        |        |
| Atazanavir                      | 88 (32.0 %) |
| Lopinavir                       | 51 (18.5 %) |
| Darunavir                       | 23 (8.4 %) |
| Fosamprenavir                   | 9 (3.3 %) |
| Saquinavir                      | 1 (0.4 %) |
| **Total**                       | 172 (62.6 %) |
| **Non nucleoside reverse transcriptase inhibitors (NNRTI)** |        |        |
| Efavirenz                       | 50 (18.2 %) |
| Nevirapine                      | 9 (3.3 %) |
| Rilpivirine                     | 8 (2.9 %) |
| Etravirine                      | 5 (1.8 %) |
| **Total**                       | 72 (26.2 %) |
| **3 Nucleoside reverse transcriptase inhibitors (NRTI)** |        |        |
| Abacavir-Lamivudine-Zidovudine  | 6 (2.2 %) |
| Integrase inhibitors (INI)      |        |        |
| Raltegravir                     | 24 (8.7 %) |
| CCR5 inhibitors                 |        |        |
| Maraviroc                       | 1 (0.4 %) |
| **NRTI backbone**              |        |        |
| Tenofovir disoproxil-fumarate-emtricitabine | 194 (70.5 %) |
| Abacavir-lamivudine             | 41 (14.9 %) |
| Zidovudine-lamivudine           | 12 (4.4 %) |
| **Other**                       | 28 (10.2 %) |
admit their disease condition, we found an HIV prevalence above 5 % which is more than 12 times higher than in the general Italian population [19, 20].

This discrepancy was also confirmed in newly admitted prisoners (HIV testing rate 34.2 %, HIV prevalence 3.3 %) and underline that prisons are concentrators of infectious diseases, due also to higher risk behaviours in acquiring blood born viruses (BBV) in people likely to be incarcerated. In our study we show an high rate of IVDU and tattooing/body piercing among both Italian and foreign BBV-infected inmates. For these reasons, the imprisonment period should be considered as an opportunity to treat a hard-to-reach population in freedom [21–27]. Finally, we cannot exclude the possibility that the real prevalence of HIV infection might have been underestimated by the low rate of testing.

Some findings deserve attention in our study. Firstly, foreign detainees represent 37.1 % of prisoners, the vast majority coming from low and middle-income countries where the health burden imposed by HIV is further exacerbated by poor socioeconomic conditions, the high prevalence of opportunistic infections, poor access to health care, and widespread drug circulation and abuse. Secondly, Italian prison population contains nearly one-third of prisoners with a history of drug misuse at some time in their lives. Given the interplay between transmissible diseases, drug use, low-to-middle-income countries origin and incarceration, there is a need to develop approaches to increase the acceptance of testing by raising an awareness in prisoners regarding infections. Appropriate testing pathways in prison should be optimized to ensure adequate pre- and post-test discussion, and to develop care pathways that enable treatment in prison as well as continuity of care upon release [28–32]. It is essential that prison healthcare personnel, in particular infectious disease specialists, make every effort to increase the offer of HIV screening in prison; indeed, the knowledge of HIV status among inmates is the only condition for HIV prisoners to access antiretroviral drugs and to obtain continuity of care when released [31, 32].

Moreover, we found a high proportion of patients with concomitant chronic viral hepatitis caused by HBV in 6.8 % and by HCV in 55.9 %. Patients with HBV coinfection should start antiretroviral therapy active also against HBV. The very high proportion of patients with HCV coinfection could represent a probably unique option to treat these patients. With the introduction of all-oral anti HCV directly-acting antiviral (DAA) drug combinations that eliminate interferon and its side effects, treatment uptake outside the prison setting is rapidly increasing. Some of these combination regimens have achieved sustained virologic response (SVR) in more than 90 % of some subgroups in clinical trials, including null responders to prior interferon-based treatment [33, 34]. Current evidence suggest that HIV/HCV co-infected can achieve the same percentage of response as HCV mono-infected [35]. The prison setting, with the possibility of DOT also for HCV, could represent a key option in order to obtain HCV eradication and reduce the progression of liver disease for the single patient as well as reducing the chance of transmission inside or, outside prison, after release.

Even in a prison setting, standard-of-care strategies have showed that health outcomes among HIV-infected inmates improve significantly. It is well established that the availability of combination antiretroviral therapy in prison is largely responsible for decreased AIDS-related mortality and morbidity among inmates in the recent years in high-income countries [33–38]. Our study shows that the vast majority of the known HIV-infected inmates were under therapy often taken with daily DOT. Successful HIV suppression was shown in over 72 % of treated patients who had an undetectable HIV-RNA. Nevertheless, several obstacles to HIV treatment in prison still remain. High costs, difficulties in maintaining confidentiality, lack of trust in correctional staff as well as the social dynamics of correctional facilities are all implicated as barriers to HIV treatment, as suggested by our findings.

We found that almost two out of three of the treated prisoners were given PI-based regimens compared to nearly one in four who received NNRTIs-based combination. Most patients probably then continue the regimens they receive in the community setting. The choice of PI-based HAART is probably due to the perceived low adherence by the physician in freedom and the high proportion of PI-based schedules is the continuation of ongoing treatment. However, when considering organization problems in prison, together with the need to treat prisoners with complex behaviors in a problematic context, caregivers should aim at reducing pill burden and dosing frequency [32, 37, 39–42]. The availability of single tablet regimens with good forgiveness can be an option that combines efficacy, safety and low pill burden giving the opportunity to the patients to continue such combinations even after incarceration [39–49]. It is thus mandatory to remember that regimen simplification can be implemented only if the suppression of HIV-RNA is ensured. Simplification can be a useful approach not only to reach successful viro-immunological outcomes among prisoners under HIV treatment, but also to improve the patient’s quality of life, maintain long-term adherence, avoid toxicities that may develop with prolonged ART and reduce the risk of virologic failure [50–52].

Although we found that over 80 % of HIV-infected inmates were treated for HIV with more than 70 % with undetectable viral load in the Italian correctional institutes, this finding does not account for the needs of
infected unaware prisoners. Nearly 67% of patients not receiving HAART at the time of the study had a CD4 cell count <350 cells/mm³, which represents the recognized threshold for therapy initiation in all international guidelines. This data highlights the need for the physician working in prison to be more proactive in convincing patients to start HAART since there is a clear benefit in terms of morbidity and mortality reduction [36–40]. The persistence of unprotected sexual relations as well as the injection of drugs without sterile equipment or with needle sharing during incarceration strengthens even more the need to test and treat HIV-infected inmates in order to reduce virus transmission, as observed in other settings [53–57].

Upon release only approximately two-third of the prisoners were followed up by infectious disease specialists. The loss to follow up of one-third of patients highly stresses the need to integrate HIV prevention and treatment services both outside and within correctional institutions. The integration of care should include access to medical discharge planning and referral to community-based HIV care providers, both being of utmost importance to guarantee continuity of care when inmates are released back into the community [58–64].

Treating HIV-infected inmates poses significant challenges, but there are several obstacles to the proper intake of anti-HIV drugs, not only due to patients. Prison doctors may be wary of managing complicated treatment regimens which often have adverse side effects, especially in high-risk populations such as IVDU. Inadequate prison infrastructures are a significant barrier to implementing comprehensive HIV care in Italy. Problems occur with patient non compliance, medical contraindications and high medication costs. Finally, inmates may be reluctant to seek testing and treatment because of fear, denial or distrust of the competence of correctional medical staff.

Conclusions
HIV treatment in Italian prisons is not uniform and this undermines the ability to provide high-quality care for the inmates infected with HIV. Diagnostics, treatment and care are offered to the majority of HIV-infected inmates, but the costs of not treating a part of this population could be significantly higher. Prisons should represent an integral part of strategies to slow down the HIV and possibly the HCV epidemic through the successful treatment of infected inmates and missed opportunities for treatment could have negative consequences not only on the incarcerated population, but on society as a whole. Therefore, nationwide programs, integrated with the National Health System, should be implemented to increase the quality of care in Italian prisons and encourage linkage to care after prison release.

Abbreviations
SIMSePe: Società Italiana Malattie e Sanità Penitenziaria; SIMIT: Società Italiana di Malattie Infettive e Tropicali; HIV: human immune deficiency virus; NNRTI: non nucleoside reverse transcriptase inhibitor; NRTI: nucleoside reverse transcriptase inhibitors; PI: Protease inhibitor; HBV: Hepatitis B Virus; HCV: Hepatitis C Virus; ART: antiretroviral therapy; DOT: daily directly observed therapy; KOP: Keep-on-person therapy; IDUs: intravenous drug users; DAA: directly-acting antiviral; SVR: sustained virologic response; AIDS: acquired immune deficiency syndrome.

Competing interest
The authors declare no conflict of interest regarding the present manuscript.

Authors’ contribution
RM, GM and SB contributed to study design, data analyses and interpretation and article writing; RR and SC contributed to interpretation of data and article writing; GL, MS, FC, SAci, DM, AAM and FAN contributed to data collection; RM and SB coordinated the project. All authors reviewed the manuscript during preparation, provided critical feedback and approved the final manuscript.

Acknowledgments
The SIMSePe-SIMIT Group includes the following members: D. Beranconi del Luca, Lecco; A. Buonorno, La Spezia; A. Casadei, Forli; M. Chiumenti, Massa; E. Conti, Padova; A. De Cicco, Reggio Calabria; V. De Marco, Bari; C. Di Filippo, Sant’Angelo dei Lombardi (AV); M. Fiscon, Verona; R. Giglio, Lauria (AV); M. Gottardi, Trento; G. Greco, Rossano Calabro (CS); L. Guastini, Terni; F. Guzzo, Belluno; B. Koechler, Viterbo; A. Manunta, Sassari; D. Palermo, Palermo; G. Panico, Carinola (CE); M. Sapienza, Enna; D. Vitucco, Alba (CN). We thank Secretariat of the Italian Society of Infectious and Tropical Diseases (SIMIT), for having organized data collection from 35 Italian correctional facilities participants to the study. Thanks also to Riccardo Raiteri, for his valuable collaboration on data organization. No funding have been received for the present study.

Author details
1 Infectious Diseases Unit, Belcolle Hospital, Viterbo, Italy. 2 Infectious Diseases Unit, Department of Clinical and Experimental Medicine, University of Sassari, Viale San Pietro 35b, 07100 Sassari, Italy. 3 Infectious Diseases Unit, A.O. San Paolo, Milan, Italy. 4 Institute of Infectious Diseases, University of Bari, Bari, Italy. 5 Infectious Diseases Unit, Amedeo di Savoia Hospital, Torino, Italy. 6 Cotugno Hospital, Infectious Diseases Unit, Naples, Italy. 7 Infectious Diseases Unit, AUSL, Parma, Italy. 8 Institute of Infectious Diseases, University of Brescia, Brescia, Italy. 9 Infectious Diseases Unit, A.O. Santa Maria alle Scorte, Siena, Italy. 10 Penitentiary Medicine, Padova, Italy.

Received: 12 August 2015 Accepted: 30 November 2015 Published online: 10 December 2015

References
1. Semaille C, Le Strat Y, Chion E, Chemilal K, Valantin MA, Serre P, et al. Prevalence of human immunodeficiency virus and hepatitis C virus among French prison inmates in 2010: a challenge for public health policy. Euro Surveillance 2013; 18 (28).
2. Fazel S, Ballenger J. The health of prisoners. Lancet. 2011;377(9769):956–65.
3. Dolan K, Kite B, Black E, Acerjas C, Simson GV. HIV in prison in low-income and middle-income countries. Lancet Infect Dis. 2007;7(1):32–41.
4. Rolly M, Weilandt C, Bird SM, Kall K, Van Haasterh HJ, Iandolo E, et al. Surveillance of HIV infection and related risk behaviour in European prisons. A multicentre pilot study, Euro J Public Health. 2001;11(2):243–50.
5. Marco A, Saiz de la Hoya P, García-Guerrero J, Grupo PREVALHEP. Multi-centre study of the prevalence of infection from HIV and associated factors in Spanish prisons. Rev Esp Sanid Penit. 2012;14(1):19–27.
6. Chan S, Marsh K, Lau R, Pakanathan M, Hughes G. An audit of HIV care in English prisons. Int J STD AIDS. 2015;26:504–8.
7. Sagnelli E, Starnini G, Sagnelli C, Monarca R, Zumbo G, Pontali E, et al. Blood borne viral infections, sexually transmitted diseases and latent tuberculosis in Italian prisons: a preliminary report of a large multicenter study. Eur Rev Med Pharmacol Sci. 2012;16(15):2142–6.
8. Westergaard RP, Spaulding AC, Flanigan TP. HIV among persons incarcerated in the USA: a review of evolving concepts in testing, treatment, and linkage to community care. Curr Opin Infect Dis. 2013;26(1):10-6. doi:10.1097/QCO.0b013e32835c1dd0.

9. Sordo del Castillo L, Ruíz-Pérez I, CitlyLabry de Lima A, SotoBlanco JM, AntónBasanta JJ, Girela López E, et al. Factors related to refuse antiretroviral therapy in prison. Gac Sanit. 2008;22(2):102–7.

10. Babudieri S, Stamini G, Brunetti B, Carbonara S, D’Orioff GP, Monara R, et al. HIV and related infections in Italian penal institutions: epidemiological and health organization note. Annali Istituto Superiore di Sanità. 2003;39(2):251–7.

11. Dell’Isola S, Catellani E, Ialungo A, Rastrelli E, Liguori E, Stamini G. Detention and incompatibility of HIV patients in Italy. Annali Istituto Superiore di Sanità. 2013;49(4):332–3.

12. Springer SA, Atlice FL. Managing HIV/AIDS in correctional settings. Curr HIV/AIDS Rep. 2005;2(4):165–70.

13. Meyer JP, Cepeda J, Wu J, Trestman RL, Atlice FL, Springer SA. Optimization of human immunodeficiency virus testing during incarceration: viral suppression at the prison gate. JAMA Intern Med. 2014;174(5):211–9.

14. Pontali E. Antiretroviral treatment in correctional facilities. HIV Clinical Trials. 2005;6(1):25–37.

15. Zaller N, Thumond P, Rich JD. Limited spending: an analysis of correctional expenditures on antiretrovirals for HIV-infected prisoners. Public Health Rep. 2007;122(1):49–54.

16. Springer SA, Friedland GH, Doros G, Pesanti E, Atlice FL. Antiretroviral treatment regimen outcomes among HIV-infected prisoners. HIV Clin Trials. 2006;7(6):267–71.

17. Babudieri S, Longo B, Sarmati L, Stamini G, Dori L, Suligoj B, et al. Correlates of HIV, HBV, and HCV infections in a prison inmate population: results from a multicentre study in Italy. J Med Virol. 2005;76:311–7.

18. Esposito M. The health of Italian prison inmates today: a critical approach. J Correct Health Care. 2010;16(3):230–6.

19. Global report: UNAIDS report on the global AIDS epidemic 2012. Available at: http://www.unaids.org/en/resources/campaigns/20121121_20_globalreport2012/globalreport. Accessed 9 Dec 2015.

20. Camoni L, Regine V, Stanecki K, Salfa MC, Raimondo M, Suligoi B. Estimates of the number of people living with HIV in Italy. Bio Med Res Int. 2011;2011:550179.

21. Bolin P, Laporte JD, Harding TW. HIV prevention in prisons. Do international guidelines matter? Eur J Public Health. 2002;12:839–43.

22. European Centre for Disease Prevention and Control. Thematic report: Prisoners. Monitoring implementation of the Dublin Declaration on Partnership to Fight HIV/AIDS in Europe and Central Asia. 2012 Progress Report. Stockholm: ECDC; 2013.

23. Dipartimento dell’amministrazione penitenziaria Ufficio per lo sviluppo e la gestione del sistema informatizzato automatizzato statistica ed automazione di supporto dipartimentale. Sezione Statistica. Available at: http://www.giustizia.it/attach/realizzazione/2009/12/20/427185713148.pdf. Accessed 9 Dec 2015.

24. Beckwith CG, Zaller ND, Fu JJ, Montague BT, Rich JD. Opportunities to diagnose, treat, and prevent HIV in the criminal justice system. J Acquir Immune Defic Syndr. 2010;53(1):40–55.

25. Solomon L, Montague BT, Beckwith CG, Baillargeon J, Costa M, Dumont D, et al. Survey finds that many prisons and jails have room to improve HIV testing and coordination of postrelease treatment. Health Aff (Millwood). 2014;33(3):434–42.

26. Spaulding AC, Booker CA, Freeman SH, Ball SW, Stein MS, Jordan AO, et al. Jails, HIV testing, and linkage to care services: an overview of the EnhanceLink initiative. AIDS Behav. 2013;17(5):100–7.

27. Beckwith CG, Cohen J, Herme M, Wickersham J, Atlice FL. Rationale, study design and sample characteristics of a randomized controlled trial of directly administered antiretroviral therapy for HIV-infected prisoners transitioning to the community—a potential conduit to pegylated interferon and ribavirin and treatment-naïve patients: the COSMOS randomised study. Lancet. 2014;384(9956):1756–65.

28. Babudieri S, Aceti A, D’Orioff GP, Carbonara S, Stamini G. Directly observed therapy to treat HIV infection in prisoners. JAMA. 2002;288(2):179–80.

29. Saber-Tehrani AS, Springer SA, Qiu J, Herme M, Wickersham J, Atlice FL. Public health implications for directly observed antiretroviral therapy among human immunodeficiency virus-infected prison inmates. Clin Infect Dis. 2003;36(12):1572–7.

30. Babudieri S, Aceti A, D’Orioff GP, Carbonara S, Stamini G. Directly observed therapy to treat chronic Hepatitis C virus infection. N Engl J Med. 2014;370(3):211–6.

31. Babudieri S, Aceti A, D’Orioff GP, Carbonara S, Stamini G. Directly observed therapy to treat chronic HCV infection. N Engl J Med. 2014;370(3):211–6.

32. Beckwith CG, Zaller ND, Fu JJ, Montague BT, Rich JD. Opportunities to diagnose, treat, and prevent HIV in the criminal justice system. J Acquir Immune Defic Syndr. 2010;53(1):40–55.

33. Shrestha RK, Sansom SL, Richardson-Moore A, French PT, Scalco B, Lalota M, et al. Costs of voluntary rapid HIV testing and counseling in jails in 4 states—advancing HIV Prevention Demonstration Project, 2003-2006. Sex Transm Dis. 2009;36(2):S5–8.

34. Bauserman RL, Richardson D, Ward M, Shea M, Bowlin C, Tomoyasu N, et al. Increasing voluntary HIV testing by offering oral tests in incarcerated populations. AIDS Educ Prev. 2003;15(5):465–80.

35. Centers for Disease Control and Prevention. HIV testing implementation guidance for correctional settings. Atlanta: Centers for Disease Control and Prevention; 2009:1–8. http://www.cdc.gov/hiv/topics/testing/resources/guidelines/correctional-settings.

36. Beckwith CG, Cohen J, Shannon C, Raz L, Rich JD, Lally MA. HIV testing experiences among male and female inmates in Rhode Island. AIDS Read. 2007;17(9):565–69.

37. Bolenko S, Hiller M, Visher C, Copenhagen M, O’Connell D, Burdon W, et al. Policies and practices in the delivery of HIV services in correctional agencies and facilities: results from a multisite survey. J Correct Health Care. 2013;49(4):293–310.

38. CDC. HIV testing implementation guidance for correctional settings. Atlanta, GA: US Department of Health and Human Services, CDC; 2009.
51. Maggiolo F, Ripamonti D, Arici C, Gregis G, Quinzan G, Camacho GA, et al. Simpler regimens may enhance adherence to antiretrovirals in HIV-infected patients. HIV Clin Trials. 2002;3:371–8.

52. Parienti JJ, Bangsberg DR, Verdon R, Gardner EM. Better adherence with once-daily antiretroviral regimens: a meta-analysis. Clin Infect Dis. 2009;48(4):484–8.

53. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.

54. Ravilja J, Vasilj I, Marijanović I, Vasilj M. Risk behaviour of prison inmates in relation to HIV/STI. Psychiatr Danub. 2014;26(2):395–401.

55. Lyons T, Osunkoya E, Anguh I, Adefuye A, Balogun J. HIV prevention and education in state prison systems: an update. J Correct Health Care. 2014;20(2):105–15.

56. Beckwith C, Bazerman L, Gillani F, Tran L, Larson B, Rivard S, et al. The feasibility of implementing the HIV seek, test, and treat strategy in jails. AIDS Patient Care STDS. 2014;28(4):183–7.

57. Farel CE, Parker SD, Muessig KE, Grodensky CA, Jones C, Golin CE, et al. Sexuality, sexual practices and HIV risk among incarcerated African-American women in North Carolina. Womens Health Issues. 2013;23(6):357–64.

58. Binswanger IA, Stern MF, Deyo RA, Heagerty PJ, Cheadle A, Elmore JG, et al. Release from prison - a high risk of death for former inmates. N Engl J Med. 2007;356(2):157–65.

59. Baillargeon JG, Giordano TP, Rich JD, Wu ZH, Wells K, Pollock BH, et al. Accessing antiretroviral therapy following release from prison. JAMA. 2009;301(8):848–57.

60. Lincoln T, Kennedy S, Tuthill R, Roberts C, Conklin TJ, Hammett TM. Facilitators and barriers to continuing healthcare after jail: a community-integrated program. J Ambul Care Manage. 2006;29(1):2–16.

61. Palepu A, Tyndall MW, Chan K, Wood E, Montaner JS, Hogg RS. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes. Antivir Ther. 2004;9(5):713–9.

62. Stephenson BL, Wohl DA, Golin CE, Tien HC, Stewart P, Kaplan AH. Effect of release from prison and re-incarceration on the viral loads of HIV-infected individuals. Public Health Rep. 2005;120(1):84–8.

63. Nunn A, Cornwall A, Fu J, Bazerman L, Loevenenthal H, Beckwith C. Linking HR-positive jail inmates to treatment, care, and social services after release: results from a qualitative assessment of the COMPASS Program. J Urban Health. 2010;87(6):954–68.

64. Baillargeon JG, Giordano TP, Harzke AJ, Baillargeon G, Rich JD, Paar DP. Enrollment in outpatient care among newly released prison inmates with HIV infection. Public Health Rep. 2010;125(1):64–71.